Roledumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRoledumab
Drug Alias NameADNC洛来度单抗Anti-D monoclonal antibodyAnti-Rhesus-D-monoclonal-antibody-LFBAnti-D monoclonal antibody - LFB +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionBlood group Rh(D) polypeptide inhibitors
TargetsBlood group Rh(D) polypeptide
Therapy Area/IndicationsAnemia, HemolyticErythroblastosis, Fetal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLfb Biotechnologies Sas
China Registration ClassN/A

Develop Information

Active CompaniesLfb Biotechnologies Sas
Inactive CompaniesLaboratoire Français De Fractionnement Et De Biotechnologies
Active IndicationsErythroblastosis, Fetal
Inactive IndicationsAnemia, Hemolytic

Other Information

ATC CodeN/A
Related LinksWikipedia